EGFR and cancer: A cancer treatment might also be developed by inhibition of epidermal growth factor receptor (EGFR) (Yarden and Pines, 2012) by competitive binding to inhibit the association of its cytoplasmic juxtamembrane (JM) domain, which is essential for receptor dimerization and kinase function.